# PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the quarter with $5.5 million in cash and expects its current capital and financing plans to support operations through year-end.

 To view the full press release, visit https://ibn.fm/AvI9R

 About NRx Pharmaceuticals, Inc.

 NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

 NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

 For more information, please visit https://www.nrxpharma.com/

 About PsychedelicNewsWire

 PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.PsychedelicNewsWire.com

 Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

 PsychedelicNewsWireAustin, Texaswww.PsychedelicNewsWire.com512.354.7000 OfficeEditor@PsychedelicNewsWire.com

 PsychedelicNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/pnw/psychedelicnewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-q1-results-highlights-progress-on-ketamine-nda-and-hope-clinic-rollup/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharmaceuticals-reports-q1-2025-financial-results-and-milestone-achievements/9fc88c58962b254f01530f393eca83a6) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1ko0rpu/nrx_pharmaceuticals_reports_q1_2025_financial/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/16/jinxlc5v.webp)